William W. Barrow - Concepedia

Author

William W. Barrow

Also Known As

Vernon Tate, W BARROW, W W BARROW, W W Barrow, W. Barrow, W. W. Barrow, W.W Barrow, W.W. BARROW, W.W. Barrow, William Barrow

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Oklahoma State University Southern Research Institute American College of Osteopathic Obstetricians & Gynecologists Institut Pasteur de la Guadeloupe Kindeva Drug Delivery (United States)

About

William W. Barrow is an author at Oklahoma State University specializing in medicine, microbiology, and tuberculosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	1.1K
2	Health Sciences	6	6	268
3	Natural Sciences	4	4	119
4	Allergy	4	4	142
5	Engineering	3	3	66

William W. Barrow

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Use of Microsphere Technology for Targeted Delivery of Rifampin to <i>Mycobacterium tuberculosis</i> -Infected Macrophages Esther L. W. Barrow, Gary A. Winchester, Jay K. Staas, Antimicrobial Agents and Chemotherapy	1998	113
Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis Ze‐Qi Xu, William W. Barrow, William J. Suling, Bioorganic & Medicinal Chemistry Pulmonary TuberculosisAntiviral CompoundHealth SciencesMedicineMycobacterium Tuberculosis	2004	103
Peptidoglycolipid nature of the superficial cell wall sheath of smooth-colony-forming mycobacteria William W. Barrow, B P Ullom, Patrick J. Brennan Journal of Bacteriology Medical MicrobiologySmooth-colony-forming MycobacteriaGram-negative BacteriologyPathogenic MicrobiologyMicrobial Disease	1980	91
Synergistic activities of antituberculous drugs with cerulenin and<i>trans</i>-cinnamic acid against<i>Mycobacterium tuberculosis</i> Nalin Rastogi, Khye Seng Goh, Lionel Horgen, FEMS Immunology & Medical Microbiology Tuberculosis PreventionAntimicrobial ChemotherapyDrug ResistanceDrug ActivityAntituberculous Drugs	1998	87
Isolation in high frequency of rough variants of Mycobacterium intracellulare lacking C-mycoside glycopeptidolipid antigens William W. Barrow, Patrick J. Brennan Journal of Bacteriology BiologyMedical MicrobiologyRough MorphologyPathogenesisImmunology	1982	83
Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase William J. Suling, Lainne E. Seitz, Vibha Pathak, Antimicrobial Agents and Chemotherapy	2000	73
Postphagocytic detection of glycopeptidolipids associated with the superficial L1 layer of Mycobacterium intracellulare M J Tereletsky, William W. Barrow Infection and Immunity Immunocytochemical TechniqueLaboratory ImmunologyGlycobiologyImmunologyPathology	1983	62
Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase William J. Suling, Robert C. Reynolds, Esther W. Barrow, Journal of Antimicrobial Chemotherapy Antimicrobial ChemotherapyPharmaceutical ChemistryMycobacterium Avium ComplexDrug ResistanceM. Tuberculosis	1998	57
Immunomodulatory spectrum of lipids associated with Mycobacterium avium serovar 8 William W. Barrow, Terry L. Davis, E L Wright, Infection and Immunity Lipid AnalysisLipid PeroxidationBacteriologyImmunologyOxidative Stress	1995	51
Modified lymphocyte response to mitogens after intraperitoneal injection of glycopeptidolipid antigens from Mycobacterium avium complex P E Brownback, William W. Barrow Infection and Immunity ImmunologyImmunodominanceImmunologic MechanismAntigen ProcessingImmunotherapy	1988	45

Page 1